PMID- 24996529
OWN - NLM
STAT- MEDLINE
DCOM- 20160422
LR  - 20211021
IS  - 1435-5604 (Electronic)
IS  - 0914-8779 (Linking)
VI  - 33
IP  - 4
DP  - 2015 Jul
TI  - Efficacy and safety of odanacatib treatment for patients with osteoporosis: a 
      meta-analysis.
PG  - 448-54
LID - 10.1007/s00774-014-0609-3 [doi]
AB  - The aim of this study was to evaluate the efficacy and safety of odanacatib (ODN) 
      for the treatment of osteoporosis, using data in studies reported in the 
      literature. We performed a literature search to compare the outcomes of 
      applications of once-weekly ODN 50 mg and control. The outcomes of osteoporosis 
      evaluated include primary outcome as bone mineral density (BMD) at different 
      skeletal sites, and secondary outcomes, including adverse events (AEs), such as 
      incidence of skin AEs, fracture, and serious adverse events (SAEs). Four trials 
      were included. Mean difference (95% CI) of lumbar spine BMD was 3.41 (1.57-5.24) 
      at 12 months and 4.89 (2.72-7.05) at 24 months; mean difference (95% CI) of 
      femoral neck BMD was 1.90 (0.73-3.08) at 12 months and 3.85 (2.55-5.15) at 24 
      months; mean difference (95% CI) of total hip BMD was 2.65 (1.20-4.09) at 12 
      months and 3.70 (1.76-5.64) at 24 months; risk ratio (95% CI) of AEs was 0.98 
      (0.91-1.07); risk ratio (95% CI) of SAEs was 1.11 (0.72-1.72); risk ratio (95% 
      CI) of skin AEs was 0.92 (0.63-1.35); and risk ratio (95% CI) of fracture was 
      0.34 (0.16-0.70). In this study, application of 50 mg ODN produced significantly 
      greater BMD increases and lower fracture incidence than that of the control. In 
      addition, ODN was generally well tolerated.
FAU - Feng, Shi
AU  - Feng S
AD  - Department of Orthopaedic Surgery, Shengjing Hospital, China Medical University, 
      36 Sanhao Road, Shenyang, 110004, China.
FAU - Luo, Zhicheng
AU  - Luo Z
FAU - Liu, Da
AU  - Liu D
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20140705
PL  - Japan
TA  - J Bone Miner Metab
JT  - Journal of bone and mineral metabolism
JID - 9436705
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Bone Density Conservation Agents)
RN  - N673F6W2VH (odanacatib)
SB  - IM
MH  - Biphenyl Compounds/adverse effects/*therapeutic use
MH  - Bone Density/drug effects
MH  - Bone Density Conservation Agents/adverse effects/*therapeutic use
MH  - Femur Neck/drug effects
MH  - Humans
MH  - Lumbar Vertebrae/drug effects
MH  - Osteoporosis/*drug therapy
MH  - Pelvic Bones/drug effects
MH  - Risk
MH  - Treatment Outcome
EDAT- 2014/07/06 06:00
MHDA- 2016/04/23 06:00
CRDT- 2014/07/06 06:00
PHST- 2014/02/27 00:00 [received]
PHST- 2014/05/25 00:00 [accepted]
PHST- 2014/07/06 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2016/04/23 06:00 [medline]
AID - 10.1007/s00774-014-0609-3 [doi]
PST - ppublish
SO  - J Bone Miner Metab. 2015 Jul;33(4):448-54. doi: 10.1007/s00774-014-0609-3. Epub 
      2014 Jul 5.